Starling Oncology, Inc. (NASDAQ: STLN) Stock Competitors & Peer Comparison
See STLN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for STLN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STLN | $5.93 | -0.67% | 592.9M | N/A | N/A | N/A |
| HCA | $405.00 | -1.03% | 87.7B | 13.99 | $28.96 | +0.74% |
| THC | $265.05 | +0.59% | 21.3B | 15.37 | $17.24 | N/A |
| FMS | $22.66 | +0.85% | 12.2B | 8.52 | $2.66 | +3.81% |
| EHC | $121.79 | -0.65% | 12.1B | 20.85 | $5.84 | +0.62% |
| DVA | $183.99 | +1.28% | 11.8B | 14.37 | $12.80 | N/A |
| UHS | $169.65 | +0.26% | 10.3B | 7.53 | $22.54 | +0.47% |
| ENSG | $170.79 | -0.76% | 10B | 24.75 | $6.90 | +0.15% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| CHE | $519.84 | -0.88% | 6.8B | 24.08 | $21.61 | +0.48% |
Stock Comparison
HCA Healthcare, Inc. (NYSE: HCA)
STLN vs HCA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, HCA has a market cap of 87.7B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while HCA trades at $405.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas HCA's P/E ratio is 13.99. In terms of profitability, STLN's ROE is +2.10%, compared to HCA's ROE of -1.13%. Regarding short-term risk, STLN is less volatile compared to HCA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check HCA's competition here
Tenet Healthcare Corporation (NYSE: THC)
STLN vs THC Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, THC has a market cap of 21.3B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while THC trades at $265.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas THC's P/E ratio is 15.37. In terms of profitability, STLN's ROE is +2.10%, compared to THC's ROE of +0.51%. Regarding short-term risk, STLN is less volatile compared to THC. This indicates lower risk in terms of short-term price fluctuations for STLN.Check THC's competition here
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)
STLN vs FMS Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, FMS has a market cap of 12.2B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while FMS trades at $22.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FMS's P/E ratio is 8.52. In terms of profitability, STLN's ROE is +2.10%, compared to FMS's ROE of +0.07%. Regarding short-term risk, STLN is more volatile compared to FMS. This indicates higher risk in terms of short-term price fluctuations for STLN.Check FMS's competition here
Encompass Health Corporation (NYSE: EHC)
STLN vs EHC Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, EHC has a market cap of 12.1B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while EHC trades at $121.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas EHC's P/E ratio is 20.85. In terms of profitability, STLN's ROE is +2.10%, compared to EHC's ROE of +0.25%. Regarding short-term risk, STLN is more volatile compared to EHC. This indicates higher risk in terms of short-term price fluctuations for STLN.Check EHC's competition here
DaVita Inc. (NYSE: DVA)
STLN vs DVA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, DVA has a market cap of 11.8B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while DVA trades at $183.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas DVA's P/E ratio is 14.37. In terms of profitability, STLN's ROE is +2.10%, compared to DVA's ROE of -1.24%. Regarding short-term risk, STLN is less volatile compared to DVA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check DVA's competition here
Universal Health Services, Inc. (NYSE: UHS)
STLN vs UHS Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, UHS has a market cap of 10.3B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while UHS trades at $169.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas UHS's P/E ratio is 7.53. In terms of profitability, STLN's ROE is +2.10%, compared to UHS's ROE of +0.21%. Regarding short-term risk, STLN is less volatile compared to UHS. This indicates lower risk in terms of short-term price fluctuations for STLN.Check UHS's competition here
The Ensign Group, Inc. (NASDAQ: ENSG)
STLN vs ENSG Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, ENSG has a market cap of 10B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while ENSG trades at $170.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ENSG's P/E ratio is 24.75. In terms of profitability, STLN's ROE is +2.10%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, STLN is more volatile compared to ENSG. This indicates higher risk in terms of short-term price fluctuations for STLN.Check ENSG's competition here
Oak Street Health, Inc. (NYSE: OSH)
STLN vs OSH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas OSH's P/E ratio is -17.65. In terms of profitability, STLN's ROE is +2.10%, compared to OSH's ROE of +4.64%. Regarding short-term risk, STLN is more volatile compared to OSH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check OSH's competition here
Chemed Corporation (NYSE: CHE)
STLN vs CHE Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, CHE has a market cap of 6.8B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while CHE trades at $519.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CHE's P/E ratio is 24.08. In terms of profitability, STLN's ROE is +2.10%, compared to CHE's ROE of +0.29%. Regarding short-term risk, STLN is more volatile compared to CHE. This indicates higher risk in terms of short-term price fluctuations for STLN.Check CHE's competition here
PACS Group, Inc. (NYSE: PACS)
STLN vs PACS Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, PACS has a market cap of 6.7B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while PACS trades at $42.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PACS's P/E ratio is 22.49. In terms of profitability, STLN's ROE is +2.10%, compared to PACS's ROE of +0.27%. Regarding short-term risk, STLN is less volatile compared to PACS. This indicates lower risk in terms of short-term price fluctuations for STLN.Check PACS's competition here
Hims & Hers Health, Inc. (NYSE: HIMS)
STLN vs HIMS Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, HIMS has a market cap of 6.2B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while HIMS trades at $27.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas HIMS's P/E ratio is -43.31. In terms of profitability, STLN's ROE is +2.10%, compared to HIMS's ROE of -0.30%. Regarding short-term risk, STLN is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for STLN.Check HIMS's competition here
LHC Group, Inc. (NASDAQ: LHCG)
STLN vs LHCG Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas LHCG's P/E ratio is 82.83. In terms of profitability, STLN's ROE is +2.10%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, STLN is more volatile compared to LHCG. This indicates higher risk in terms of short-term price fluctuations for STLN.Check LHCG's competition here
LifeStance Health Group, Inc. (NASDAQ: LFST)
STLN vs LFST Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, LFST has a market cap of 4.9B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while LFST trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas LFST's P/E ratio is 95.88. In terms of profitability, STLN's ROE is +2.10%, compared to LFST's ROE of +0.03%. Regarding short-term risk, STLN is less volatile compared to LFST. This indicates lower risk in terms of short-term price fluctuations for STLN.Check LFST's competition here
Concentra Group Holdings Parent, Inc. (NYSE: CON)
STLN vs CON Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, CON has a market cap of 4.4B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while CON trades at $34.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CON's P/E ratio is 21.68. In terms of profitability, STLN's ROE is +2.10%, compared to CON's ROE of +0.47%. Regarding short-term risk, STLN is more volatile compared to CON. This indicates higher risk in terms of short-term price fluctuations for STLN.Check CON's competition here
Option Care Health, Inc. (NASDAQ: OPCH)
STLN vs OPCH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, OPCH has a market cap of 3.6B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while OPCH trades at $24.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas OPCH's P/E ratio is 14.08. In terms of profitability, STLN's ROE is +2.10%, compared to OPCH's ROE of +0.16%. Regarding short-term risk, STLN is more volatile compared to OPCH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check OPCH's competition here
National HealthCare Corporation (AMEX: NHC)
STLN vs NHC Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, NHC has a market cap of 3.4B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while NHC trades at $218.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NHC's P/E ratio is 27.76. In terms of profitability, STLN's ROE is +2.10%, compared to NHC's ROE of +0.13%. Regarding short-term risk, STLN is less volatile compared to NHC. This indicates lower risk in terms of short-term price fluctuations for STLN.Check NHC's competition here
Amedisys, Inc. (NASDAQ: AMED)
STLN vs AMED Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AMED's P/E ratio is 39.30. In terms of profitability, STLN's ROE is +2.10%, compared to AMED's ROE of +0.11%. Regarding short-term risk, STLN is more volatile compared to AMED. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AMED's competition here
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH)
STLN vs AVAH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AVAH has a market cap of 3B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AVAH trades at $13.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AVAH's P/E ratio is 19.97. In terms of profitability, STLN's ROE is +2.10%, compared to AVAH's ROE of +1.50%. Regarding short-term risk, STLN is less volatile compared to AVAH. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AVAH's competition here
Brookdale Senior Living Inc. (NYSE: BKD)
STLN vs BKD Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, BKD has a market cap of 2.8B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while BKD trades at $11.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BKD's P/E ratio is -20.30. In terms of profitability, STLN's ROE is +2.10%, compared to BKD's ROE of +4.06%. Regarding short-term risk, STLN is less volatile compared to BKD. This indicates lower risk in terms of short-term price fluctuations for STLN.Check BKD's competition here
Acadia Healthcare Company, Inc. (NASDAQ: ACHC)
STLN vs ACHC Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, ACHC has a market cap of 2.6B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while ACHC trades at $28.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ACHC's P/E ratio is 14.14. In terms of profitability, STLN's ROE is +2.10%, compared to ACHC's ROE of -0.50%. Regarding short-term risk, STLN is less volatile compared to ACHC. This indicates lower risk in terms of short-term price fluctuations for STLN.Check ACHC's competition here
Guardian Pharmacy Services, Inc. (NYSE: GRDN)
STLN vs GRDN Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, GRDN has a market cap of 2.6B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while GRDN trades at $40.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas GRDN's P/E ratio is 35.79. In terms of profitability, STLN's ROE is +2.10%, compared to GRDN's ROE of +0.31%. Regarding short-term risk, STLN is less volatile compared to GRDN. This indicates lower risk in terms of short-term price fluctuations for STLN.Check GRDN's competition here
Pediatrix Medical Group, Inc. (NYSE: MD)
STLN vs MD Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while MD trades at $27.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas MD's P/E ratio is 12.07. In terms of profitability, STLN's ROE is +2.10%, compared to MD's ROE of +0.20%. Regarding short-term risk, STLN is more volatile compared to MD. This indicates higher risk in terms of short-term price fluctuations for STLN.Check MD's competition here
Addus HomeCare Corporation (NASDAQ: ADUS)
STLN vs ADUS Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, ADUS has a market cap of 2.2B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while ADUS trades at $118.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ADUS's P/E ratio is 17.78. In terms of profitability, STLN's ROE is +2.10%, compared to ADUS's ROE of +0.10%. Regarding short-term risk, STLN is more volatile compared to ADUS. This indicates higher risk in terms of short-term price fluctuations for STLN.Check ADUS's competition here
Select Medical Holdings Corporation (NYSE: SEM)
STLN vs SEM Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, SEM has a market cap of 2B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while SEM trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SEM's P/E ratio is 15.43. In terms of profitability, STLN's ROE is +2.10%, compared to SEM's ROE of +0.08%. Regarding short-term risk, STLN is more volatile compared to SEM. This indicates higher risk in terms of short-term price fluctuations for STLN.Check SEM's competition here
Astrana Health, Inc. (NASDAQ: ASTH)
STLN vs ASTH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while ASTH trades at $38.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ASTH's P/E ratio is 46.35. In terms of profitability, STLN's ROE is +2.10%, compared to ASTH's ROE of +0.05%. Regarding short-term risk, STLN is less volatile compared to ASTH. This indicates lower risk in terms of short-term price fluctuations for STLN.Check ASTH's competition here
Surgery Partners, Inc. (NASDAQ: SGRY)
STLN vs SGRY Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, SGRY has a market cap of 1.9B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while SGRY trades at $14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SGRY's P/E ratio is 36.56. In terms of profitability, STLN's ROE is +2.10%, compared to SGRY's ROE of -0.05%. Regarding short-term risk, STLN is less volatile compared to SGRY. This indicates lower risk in terms of short-term price fluctuations for STLN.Check SGRY's competition here
Apollo Medical Holdings, Inc. (NASDAQ: AMEH)
STLN vs AMEH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AMEH's P/E ratio is 39.25. In terms of profitability, STLN's ROE is +2.10%, compared to AMEH's ROE of +0.05%. Regarding short-term risk, STLN is less volatile compared to AMEH. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AMEH's competition here
Sonida Senior Living, Inc. (NYSE: SNDA)
STLN vs SNDA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, SNDA has a market cap of 1.8B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while SNDA trades at $37.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SNDA's P/E ratio is -6.09. In terms of profitability, STLN's ROE is +2.10%, compared to SNDA's ROE of -0.26%. Regarding short-term risk, STLN is less volatile compared to SNDA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check SNDA's competition here
Ardent Health Inc. (NYSE: ARDT)
STLN vs ARDT Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, ARDT has a market cap of 1.6B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while ARDT trades at $10.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ARDT's P/E ratio is 8.79. In terms of profitability, STLN's ROE is +2.10%, compared to ARDT's ROE of +0.05%. Regarding short-term risk, STLN is less volatile compared to ARDT. This indicates lower risk in terms of short-term price fluctuations for STLN.Check ARDT's competition here
Healthcare Services Group, Inc. (NASDAQ: HCSG)
STLN vs HCSG Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while HCSG trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas HCSG's P/E ratio is 17.46. In terms of profitability, STLN's ROE is +2.10%, compared to HCSG's ROE of +0.24%. Regarding short-term risk, STLN is less volatile compared to HCSG. This indicates lower risk in terms of short-term price fluctuations for STLN.Check HCSG's competition here
Agilon Health, Inc. (NYSE: AGL)
STLN vs AGL Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AGL has a market cap of 1.5B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AGL trades at $88.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AGL's P/E ratio is -5.72. In terms of profitability, STLN's ROE is +2.10%, compared to AGL's ROE of -1.19%. Regarding short-term risk, STLN is less volatile compared to AGL. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AGL's competition here
Innovage Holding Corp. (NASDAQ: INNV)
STLN vs INNV Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, INNV has a market cap of 1.5B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while INNV trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas INNV's P/E ratio is -119.44. In terms of profitability, STLN's ROE is +2.10%, compared to INNV's ROE of -0.09%. Regarding short-term risk, STLN is less volatile compared to INNV. This indicates lower risk in terms of short-term price fluctuations for STLN.Check INNV's competition here
Nutex Health, Inc. (NASDAQ: NUTX)
STLN vs NUTX Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, NUTX has a market cap of 1.3B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while NUTX trades at $193.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NUTX's P/E ratio is 7.65. In terms of profitability, STLN's ROE is +2.10%, compared to NUTX's ROE of +0.52%. Regarding short-term risk, STLN is less volatile compared to NUTX. This indicates lower risk in terms of short-term price fluctuations for STLN.Check NUTX's competition here
The Pennant Group, Inc. (NASDAQ: PNTG)
STLN vs PNTG Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, PNTG has a market cap of 1.3B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while PNTG trades at $38.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PNTG's P/E ratio is 28.79. In terms of profitability, STLN's ROE is +2.10%, compared to PNTG's ROE of +0.10%. Regarding short-term risk, STLN is less volatile compared to PNTG. This indicates lower risk in terms of short-term price fluctuations for STLN.Check PNTG's competition here
AMN Healthcare Services, Inc. (NYSE: AMN)
STLN vs AMN Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AMN trades at $33.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AMN's P/E ratio is 11.23. In terms of profitability, STLN's ROE is +2.10%, compared to AMN's ROE of +0.15%. Regarding short-term risk, STLN is less volatile compared to AMN. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AMN's competition here
Brookdale Senior Living Inc. 7. (NYSE: BKDT)
STLN vs BKDT Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BKDT's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to BKDT's ROE of +4.06%. Regarding short-term risk, STLN is more volatile compared to BKDT. This indicates higher risk in terms of short-term price fluctuations for STLN.Check BKDT's competition here
U.S. Physical Therapy, Inc. (NYSE: USPH)
STLN vs USPH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while USPH trades at $79.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas USPH's P/E ratio is 31.25. In terms of profitability, STLN's ROE is +2.10%, compared to USPH's ROE of -0.01%. Regarding short-term risk, STLN is less volatile compared to USPH. This indicates lower risk in terms of short-term price fluctuations for STLN.Check USPH's competition here
Talkspace, Inc. (NASDAQ: TALK)
STLN vs TALK Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, TALK has a market cap of 879.4M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while TALK trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TALK's P/E ratio is 774.34. In terms of profitability, STLN's ROE is +2.10%, compared to TALK's ROE of +0.00%. Regarding short-term risk, STLN is more volatile compared to TALK. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TALK's competition here
GMR Solutions Inc. (NYSE: GMRS)
STLN vs GMRS Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, GMRS has a market cap of 728.1M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while GMRS trades at $13.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas GMRS's P/E ratio is 5.99. In terms of profitability, STLN's ROE is +2.10%, compared to GMRS's ROE of +0.16%. Regarding short-term risk, STLN is less volatile compared to GMRS. This indicates lower risk in terms of short-term price fluctuations for STLN.Check GMRS's competition here
Enhabit, Inc. (NYSE: EHAB)
STLN vs EHAB Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas EHAB's P/E ratio is -197.14. In terms of profitability, STLN's ROE is +2.10%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, STLN is more volatile compared to EHAB. This indicates higher risk in terms of short-term price fluctuations for STLN.Check EHAB's competition here
The Oncology Institute, Inc. (NASDAQ: TOI)
STLN vs TOI Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, TOI has a market cap of 512.9M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while TOI trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TOI's P/E ratio is -14.25. In terms of profitability, STLN's ROE is +2.10%, compared to TOI's ROE of +2.10%. Regarding short-term risk, STLN is less volatile compared to TOI. This indicates lower risk in terms of short-term price fluctuations for STLN.Check TOI's competition here
Strata Critical Medical, Inc. (NASDAQ: SRTA)
STLN vs SRTA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, SRTA has a market cap of 460.3M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while SRTA trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SRTA's P/E ratio is -25.08. In terms of profitability, STLN's ROE is +2.10%, compared to SRTA's ROE of +0.14%. Regarding short-term risk, STLN is less volatile compared to SRTA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check SRTA's competition here
Charming Medical Limited Class A Ordinary Shares (NASDAQ: MCTA)
STLN vs MCTA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas MCTA's P/E ratio is 419.36. In terms of profitability, STLN's ROE is +2.10%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, STLN is more volatile compared to MCTA. This indicates higher risk in terms of short-term price fluctuations for STLN.Check MCTA's competition here
Community Health Systems, Inc. (NYSE: CYH)
STLN vs CYH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, CYH has a market cap of 406.8M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while CYH trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CYH's P/E ratio is 3.95. In terms of profitability, STLN's ROE is +2.10%, compared to CYH's ROE of +0.21%. Regarding short-term risk, STLN is more volatile compared to CYH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check CYH's competition here
Auna S.A. (NYSE: AUNA)
STLN vs AUNA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AUNA has a market cap of 391.6M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AUNA trades at $5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AUNA's P/E ratio is 4.77. In terms of profitability, STLN's ROE is +2.10%, compared to AUNA's ROE of +0.01%. Regarding short-term risk, STLN is less volatile compared to AUNA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AUNA's competition here
Viemed Healthcare, Inc. (NASDAQ: VMD)
STLN vs VMD Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, VMD has a market cap of 345.8M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while VMD trades at $9.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas VMD's P/E ratio is 25.22. In terms of profitability, STLN's ROE is +2.10%, compared to VMD's ROE of +0.10%. Regarding short-term risk, STLN is less volatile compared to VMD. This indicates lower risk in terms of short-term price fluctuations for STLN.Check VMD's competition here
Capital Senior Living Corporation (NYSE: CSU)
STLN vs CSU Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CSU's P/E ratio is 0.67. In terms of profitability, STLN's ROE is +2.10%, compared to CSU's ROE of -0.33%. Regarding short-term risk, STLN is less volatile compared to CSU. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CSU's competition here
AirSculpt Technologies, Inc. (NASDAQ: AIRS)
STLN vs AIRS Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AIRS has a market cap of 197.2M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AIRS trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AIRS's P/E ratio is -93.17. In terms of profitability, STLN's ROE is +2.10%, compared to AIRS's ROE of -0.13%. Regarding short-term risk, STLN is less volatile compared to AIRS. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AIRS's competition here
The Joint Corp. (NASDAQ: JYNT)
STLN vs JYNT Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, JYNT has a market cap of 118.6M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while JYNT trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas JYNT's P/E ratio is 83.20. In terms of profitability, STLN's ROE is +2.10%, compared to JYNT's ROE of +0.22%. Regarding short-term risk, STLN is less volatile compared to JYNT. This indicates lower risk in terms of short-term price fluctuations for STLN.Check JYNT's competition here
Five Star Senior Living Inc. (NASDAQ: FVE)
STLN vs FVE Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FVE's P/E ratio is -5.64. In terms of profitability, STLN's ROE is +2.10%, compared to FVE's ROE of -0.15%. Regarding short-term risk, STLN is less volatile compared to FVE. This indicates lower risk in terms of short-term price fluctuations for STLN.Check FVE's competition here
Kindly MD, Inc. (NASDAQ: KDLYW)
STLN vs KDLYW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas KDLYW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to KDLYW's ROE of -1.05%. Regarding short-term risk, STLN is less volatile compared to KDLYW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check KDLYW's competition here
Park Dental Partners, Inc. Common Stock (NASDAQ: PARK)
STLN vs PARK Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, PARK has a market cap of 92.2M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while PARK trades at $20.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PARK's P/E ratio is 27.61. In terms of profitability, STLN's ROE is +2.10%, compared to PARK's ROE of -0.18%. Regarding short-term risk, STLN is less volatile compared to PARK. This indicates lower risk in terms of short-term price fluctuations for STLN.Check PARK's competition here
biote Corp. (NASDAQ: BTMD)
STLN vs BTMD Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, BTMD has a market cap of 68.1M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while BTMD trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BTMD's P/E ratio is 14.05. In terms of profitability, STLN's ROE is +2.10%, compared to BTMD's ROE of -0.09%. Regarding short-term risk, STLN is less volatile compared to BTMD. This indicates lower risk in terms of short-term price fluctuations for STLN.Check BTMD's competition here
AlerisLife Inc. (NASDAQ: ALR)
STLN vs ALR Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ALR's P/E ratio is -1.11. In terms of profitability, STLN's ROE is +2.10%, compared to ALR's ROE of -0.15%. Regarding short-term risk, STLN is more volatile compared to ALR. This indicates higher risk in terms of short-term price fluctuations for STLN.Check ALR's competition here
DocGo Inc. (NASDAQ: DCGO)
STLN vs DCGO Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, DCGO has a market cap of 39.8M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while DCGO trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas DCGO's P/E ratio is -0.22. In terms of profitability, STLN's ROE is +2.10%, compared to DCGO's ROE of -1.16%. Regarding short-term risk, STLN is less volatile compared to DCGO. This indicates lower risk in terms of short-term price fluctuations for STLN.Check DCGO's competition here
Cryo-Cell International, Inc. (AMEX: CCEL)
STLN vs CCEL Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, CCEL has a market cap of 34.5M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while CCEL trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CCEL's P/E ratio is -14.27. In terms of profitability, STLN's ROE is +2.10%, compared to CCEL's ROE of +0.14%. Regarding short-term risk, STLN is less volatile compared to CCEL. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CCEL's competition here
IMAC Holdings, Inc. (NASDAQ: IMAC)
STLN vs IMAC Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas IMAC's P/E ratio is -2.27. In terms of profitability, STLN's ROE is +2.10%, compared to IMAC's ROE of +0.00%. Regarding short-term risk, STLN is less volatile compared to IMAC. This indicates lower risk in terms of short-term price fluctuations for STLN.Check IMAC's competition here
P3 Health Partners Inc. (NASDAQ: PIII)
STLN vs PIII Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, PIII has a market cap of 30.6M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while PIII trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PIII's P/E ratio is -0.28. In terms of profitability, STLN's ROE is +2.10%, compared to PIII's ROE of +1.61%. Regarding short-term risk, STLN is less volatile compared to PIII. This indicates lower risk in terms of short-term price fluctuations for STLN.Check PIII's competition here
EUDA Health Holdings Limited (NASDAQ: EUDA)
STLN vs EUDA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, EUDA has a market cap of 25.4M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while EUDA trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas EUDA's P/E ratio is -25.66. In terms of profitability, STLN's ROE is +2.10%, compared to EUDA's ROE of +1.20%. Regarding short-term risk, STLN is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check EUDA's competition here
P3 Health Partners Inc. (NASDAQ: PIIIW)
STLN vs PIIIW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, PIIIW has a market cap of 24.5M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PIIIW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to PIIIW's ROE of +1.61%. Regarding short-term risk, STLN is less volatile compared to PIIIW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check PIIIW's competition here
Cano Health, Inc. (NYSE: CANO-WT)
STLN vs CANO-WT Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, STLN is less volatile compared to CANO-WT. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CANO-WT's competition here
Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH)
STLN vs AIH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AIH's P/E ratio is -2.78. In terms of profitability, STLN's ROE is +2.10%, compared to AIH's ROE of +1.16%. Regarding short-term risk, STLN is less volatile compared to AIH. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AIH's competition here
Cano Health, Inc. (NYSE: CANO)
STLN vs CANO Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CANO's P/E ratio is -0.01. In terms of profitability, STLN's ROE is +2.10%, compared to CANO's ROE of -1.49%. Regarding short-term risk, STLN is less volatile compared to CANO. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CANO's competition here
Avem Health Partners, Inc. (NYSE: FPCG)
STLN vs FPCG Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FPCG's P/E ratio is 0.09. In terms of profitability, STLN's ROE is +2.10%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, STLN is more volatile compared to FPCG. This indicates higher risk in terms of short-term price fluctuations for STLN.Check FPCG's competition here
Field Trip Health Ltd. (NASDAQ: FTRP)
STLN vs FTRP Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FTRP's P/E ratio is -1.22. In terms of profitability, STLN's ROE is +2.10%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, STLN is less volatile compared to FTRP. This indicates lower risk in terms of short-term price fluctuations for STLN.Check FTRP's competition here
American Shared Hospital Services (AMEX: AMS)
STLN vs AMS Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AMS has a market cap of 9.5M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AMS trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AMS's P/E ratio is -5.66. In terms of profitability, STLN's ROE is +2.10%, compared to AMS's ROE of -0.07%. Regarding short-term risk, STLN is less volatile compared to AMS. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AMS's competition here
Basel Medical Group Ltd Ordinary Shares (NASDAQ: BMGL)
STLN vs BMGL Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, BMGL has a market cap of 7.6M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while BMGL trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BMGL's P/E ratio is -0.91. In terms of profitability, STLN's ROE is +2.10%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, STLN is less volatile compared to BMGL. This indicates lower risk in terms of short-term price fluctuations for STLN.Check BMGL's competition here
20/20 Biolabs Inc. (NASDAQ: AIDX)
STLN vs AIDX Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AIDX has a market cap of 7.2M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AIDX trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AIDX's P/E ratio is -1.12. In terms of profitability, STLN's ROE is +2.10%, compared to AIDX's ROE of -3.87%. Regarding short-term risk, STLN is less volatile compared to AIDX. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AIDX's competition here
ModivCare Inc. (NASDAQ: MODV)
STLN vs MODV Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas MODV's P/E ratio is -0.06. In terms of profitability, STLN's ROE is +2.10%, compared to MODV's ROE of +1.36%. Regarding short-term risk, STLN is more volatile compared to MODV. This indicates higher risk in terms of short-term price fluctuations for STLN.Check MODV's competition here
Starling Oncology Inc. Wt (NASDAQ: STLNW)
STLN vs STLNW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, STLNW has a market cap of 5.5M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while STLNW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas STLNW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to STLNW's ROE of +2.10%. Regarding short-term risk, STLN is more volatile compared to STLNW. This indicates higher risk in terms of short-term price fluctuations for STLN.Check STLNW's competition here
Greenbrook TMS Inc. (NASDAQ: GBNH)
STLN vs GBNH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas GBNH's P/E ratio is -0.06. In terms of profitability, STLN's ROE is +2.10%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, STLN is less volatile compared to GBNH. This indicates lower risk in terms of short-term price fluctuations for STLN.Check GBNH's competition here
Regional Health Properties, Inc. (AMEX: RHE-PA)
STLN vs RHE-PA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, STLN's ROE is +2.10%, compared to RHE-PA's ROE of +1.09%. Regarding short-term risk, STLN is less volatile compared to RHE-PA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check RHE-PA's competition here
Regional Health Properties, Inc. (AMEX: RHE)
STLN vs RHE Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas RHE's P/E ratio is -1.79. In terms of profitability, STLN's ROE is +2.10%, compared to RHE's ROE of -1.31%. Regarding short-term risk, STLN is less volatile compared to RHE. This indicates lower risk in terms of short-term price fluctuations for STLN.Check RHE's competition here
The Oncology Institute, Inc. (NASDAQ: TOIIW)
STLN vs TOIIW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, TOIIW has a market cap of 4.7M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TOIIW's P/E ratio is -0.17. In terms of profitability, STLN's ROE is +2.10%, compared to TOIIW's ROE of +2.10%. Regarding short-term risk, STLN is more volatile compared to TOIIW. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TOIIW's competition here
IMAC Holdings, Inc. (NASDAQ: IMACW)
STLN vs IMACW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas IMACW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to IMACW's ROE of +0.73%. Regarding short-term risk, STLN is less volatile compared to IMACW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check IMACW's competition here
Endovia Health Sciences, Inc. (AMEX: EDVA)
STLN vs EDVA Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, EDVA has a market cap of 1.7M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while EDVA trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas EDVA's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to EDVA's ROE of N/A. Regarding short-term risk, STLN is less volatile compared to EDVA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check EDVA's competition here
EUDA Health Holdings Limited (NASDAQ: EUDAW)
STLN vs EUDAW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, EUDAW has a market cap of 1.1M. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas EUDAW's P/E ratio is 0.04. In terms of profitability, STLN's ROE is +2.10%, compared to EUDAW's ROE of +1.20%. Regarding short-term risk, STLN is less volatile compared to EUDAW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check EUDAW's competition here
Concord Medical Services Holdings Limited (NYSE: CCM)
STLN vs CCM Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, CCM has a market cap of 642.2K. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while CCM trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CCM's P/E ratio is -0.30. In terms of profitability, STLN's ROE is +2.10%, compared to CCM's ROE of +0.06%. Regarding short-term risk, STLN is less volatile compared to CCM. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CCM's competition here
NewGenIvf Group Limited (NASDAQ: NIVF)
STLN vs NIVF Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, NIVF has a market cap of 72K. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while NIVF trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NIVF's P/E ratio is 0.56. In terms of profitability, STLN's ROE is +2.10%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, STLN is less volatile compared to NIVF. This indicates lower risk in terms of short-term price fluctuations for STLN.Check NIVF's competition here
NewGenIvf Group Limited (NASDAQ: NIVFW)
STLN vs NIVFW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, NIVFW has a market cap of 45.5K. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, STLN's ROE is +2.10%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, STLN is more volatile compared to NIVFW. This indicates higher risk in terms of short-term price fluctuations for STLN.Check NIVFW's competition here
Mobile-health Network Solutions Class A Ordinary Shares (NASDAQ: MNDR)
STLN vs MNDR Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, MNDR has a market cap of 34.9K. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while MNDR trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas MNDR's P/E ratio is -0.04. In terms of profitability, STLN's ROE is +2.10%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, STLN is less volatile compared to MNDR. This indicates lower risk in terms of short-term price fluctuations for STLN.Check MNDR's competition here
Talkspace, Inc. (NASDAQ: TALKW)
STLN vs TALKW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, TALKW has a market cap of 33.5K. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TALKW's P/E ratio is 0.00. In terms of profitability, STLN's ROE is +2.10%, compared to TALKW's ROE of +0.00%. Regarding short-term risk, STLN is less volatile compared to TALKW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check TALKW's competition here
Skylight Health Group Inc. (NASDAQ: SLHG)
STLN vs SLHG Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SLHG's P/E ratio is -1.48. In terms of profitability, STLN's ROE is +2.10%, compared to SLHG's ROE of N/A. Regarding short-term risk, STLN is less volatile compared to SLHG. This indicates lower risk in terms of short-term price fluctuations for STLN.Check SLHG's competition here
Skylight Health Group Inc. (NASDAQ: SLHGP)
STLN vs SLHGP Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, STLN's ROE is +2.10%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, STLN is more volatile compared to SLHGP. This indicates higher risk in terms of short-term price fluctuations for STLN.Check SLHGP's competition here
Almost Family Inc. (NASDAQ: AFAM)
STLN vs AFAM Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, AFAM has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AFAM's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, STLN is less volatile compared to AFAM. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AFAM's competition here
SOC Telemed, Inc. (NASDAQ: TLMD)
STLN vs TLMD Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TLMD's P/E ratio is -1.60. In terms of profitability, STLN's ROE is +2.10%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, STLN is more volatile compared to TLMD. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TLMD's competition here
Hanger, Inc. (NYSE: HNGR)
STLN vs HNGR Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas HNGR's P/E ratio is 19.71. In terms of profitability, STLN's ROE is +2.10%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, STLN is more volatile compared to HNGR. This indicates higher risk in terms of short-term price fluctuations for STLN.Check HNGR's competition here
New Frontier Health Corporation (NYSE: NFH)
STLN vs NFH Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, NFH has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NFH's P/E ratio is -19.75. In terms of profitability, STLN's ROE is +2.10%, compared to NFH's ROE of -0.06%. Regarding short-term risk, STLN is more volatile compared to NFH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check NFH's competition here
Diversicare Healthcare Services, Inc. (NASDAQ: DVCR)
STLN vs DVCR Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas DVCR's P/E ratio is 28.34. In terms of profitability, STLN's ROE is +2.10%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, STLN is more volatile compared to DVCR. This indicates higher risk in terms of short-term price fluctuations for STLN.Check DVCR's competition here
ATI Physical Therapy, Inc. (NYSE: ATIP-WT)
STLN vs ATIP-WT Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, STLN is less volatile compared to ATIP-WT. This indicates lower risk in terms of short-term price fluctuations for STLN.Check ATIP-WT's competition here
SOC Telemed, Inc. (NASDAQ: TLMDW)
STLN vs TLMDW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TLMDW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, STLN is less volatile compared to TLMDW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check TLMDW's competition here
Tivity Health, Inc. (NASDAQ: TVTY)
STLN vs TVTY Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TVTY's P/E ratio is 19.06. In terms of profitability, STLN's ROE is +2.10%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, STLN is more volatile compared to TVTY. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TVTY's competition here
DocGo Inc. (NASDAQ: DCGOW)
STLN vs DCGOW Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas DCGOW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to DCGOW's ROE of -1.16%. Regarding short-term risk, STLN is less volatile compared to DCGOW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check DCGOW's competition here
Kindred Healthcare, Inc. (NYSE: KND)
STLN vs KND Comparison September 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 592.9M. In comparison, KND has a market cap of 0. Regarding current trading prices, STLN is priced at $5.93 on the NASDAQ, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas KND's P/E ratio is -1.14. In terms of profitability, STLN's ROE is +2.10%, compared to KND's ROE of -0.53%. Regarding short-term risk, STLN is more volatile compared to KND. This indicates higher risk in terms of short-term price fluctuations for STLN.Check KND's competition here